Case C-29/17 | Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others

Author (Corporate)	European Court of Justice, Information Service
Publisher	European Court of Justice (ECJ)
Series Details	C-29/17
Publication Date	2017
Content Type	Overview
	Summary: The reimbursement by a national healthcare insurance system of a medicinal product for a use not covered by its marketing authorisation (off-label use) is not contrary to EU law. However, that medicinal product must still adhere to EU pharmaceutical rules.
Source Link	Primary Source http://curia.europa.eu/juris/documents.jsf?num=C-29/17
Related Links	Official Judgment of the ECJ in Case C-29/17 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62017CJ0029 CJEU: Press Release, 21.11.2018: Judgment in Case C-29/17 Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others https://curia.europa.eu/jcms/upload/docs/application/pdf/2018-11/cp180181en.pdf
Subject Categories	Business and Industry
Subject Tags	Pharmaceuticals
Keywords	CJEU Judgments
Countries / Regions	Italy
International Organisations	European Union [EU]